ClinicalTrials.gg
CompletedNCT04110717Updated Apr 3, 2023

Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight

An interventional study of Vestal Device and Control Device in Overweight, Obesity and Overweight and Obesity, sponsored by Neurovalens Ltd.. Completed at 1 site in Ireland. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-03.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Neurovalens Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies in Obesity with a site in Ireland — 9 open to participants now, 10 under way, none of them phase 3. Obesity · Ireland.

Enrollment
27th of 32
50 · median 126
Started
2020
with 1 other
No phase
18 of 41
5 open now
Registered
22nd of 41
by date

Among the 41 studies in Obesity with a site in Ireland, this one is the 27th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2020, is one of 18 with no phase, and was the 22nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 41 studies in Obesity with a site in Ireland are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Ireland have not opened yet or have stopped. Only those recruiting at a site in Ireland →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Obesity with a site in Ireland, or all of them as a file.
02

Study summary

A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), together with a lifestyle modification program, compared to a sham control with a lifestyle modification programme, as a means of reducing excess body weight and body fat.

03

Conditions studied

  • Overweight
  • Obesity
  • Overweight and Obesity
  • Overweight or Obesity
  • Metabolic Syndrome

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's enrollment of 50 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Neurovalens Ltd. is the lead sponsor of 20 studies on the registry; 1 is open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. (BMI) ≥ 25 kg/m2 2. Males or Females. Note females of must have a negative urine pregnancy test They should agree to follow a physician-approved regimen for the duration of the study period (other than DMPA injections as this causes weight gain).

      1. 18-80 years of age inclusive on starting the study. 4. Ability and willingness to complete all study visits and procedures; in particular an agreement to engage with: trying to use the device on a daily basis; the hypocaloric diet weight loss program; and this provided weight loss support and mentoring.
      1. Agreement not to use of prescription, or over-the-counter, weight loss preparations for the duration of the trial.
      1. Agreement not to start smoking tobacco or marijuana for the duration of the study.
      1. Access to Wi-Fi (to connect iPod to internet)

Exclusion criteria

Exclusion Criteria:

    1. History of vestibular dysfunction or other inner ear disease as indicated by the screening questions.

      1. History of bariatric surgery, or gastric resection. 3. History of skin breakdown, eczema or other dermatological condition (e.g. psoriasis) affecting the skin behind the ears.
      1. History of weight loss device implantation (e.g. VBloc Maestro or Abiliti). 5. Use of a non-invasive weight loss device (e.g. Modius) 6. Hypothyroidism requiring current treatment with levothyroxine (e.g. Levo-T, Synthroid, Thyroxine) (Other thyroid disorder patients on stable treatment for at least 3 months are acceptable).
      1. Other endocrinological causes of weight gain (e.g. Cushing's disease, Cushing's syndrome or acromegaly) 8. Previous diagnosis of infection or AIDS (HIV is known to cause a vestibular neuropathy which would prevent VeNS from working).
      1. Diagnosis of cirrhosis, chronic pancreatitis, or liver, kidney or heart failure.
      1. Treatment with prescription weight-loss drug therapy in the 6 months before starting the study.
      1. Tobacco or marijuana smoking in the 6 months before starting and for the duration of the study.
      1. Known genetic cause of obesity (e.g., Prader-Willi Syndrome). 13. Body weight change of more than 20% in either direction within the previous year.
      1. Physician-prescribed diet, and/ or current, active member of an organized weight loss program.
      1. Diabetes mellitus (Types 1 \& 2). 16. Diagnosis of epilepsy or use of anti-epileptic medication within six months of starting the study (e.g. for the treatment of peripheral neuropathy) 17. Chronic (more than a month of daily use) treatment with opioid analgesic drugs within the last 6 months.
      1. Regular use (more than twice a month) of anti-histamine medication within the last 6 months.
      1. Use of oral or intravenous medication within 6 months of starting the study.
      1. Use of the beta-blockers atenolol, metoprolol or propranolol within 3 months of starting the study.
      1. Current alterations in treatment regimens of anti-depressant medication for whatever reason (including tricyclic antidepressants) (Note: stable treatment regimen for prior 6 months acceptable).
      1. An active diagnosis of cancer. 23. A myocardial infarction within the preceding year. 24. A history of stroke or severe head injury (as defined by a head injury that required craniotomy or endotracheal intubation). (In case this damaged the neurological pathways involved in vestibular stimulation).
      1. Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.).
      1. Psychiatric disorders (including untreated severe depression, schizophrenia, substance abuse, eating disorder etc.) 27. Current participant in another weight loss study or other clinical trial. 28. Have a family member who is currently participating or is planning to participate in this study.
      1. Pregnancy 30. History of migraine headaches
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Active Device Group

    25 subjects randomised to receive active device use plus lifestyle intervention for 3 months.

    Device: Vestal Device · Behavioral: Hypocaloric Diet

  • Placebo comparator
    Control Device Group

    25 subjects randomised to receive control device use plus lifestyle intervention for 3 months.

    Device: Control Device · Behavioral: Hypocaloric Diet

Interventions

  • DeviceVestal Device

    Vestibular nerve stimulator

  • DeviceControl Device

    Control Device

  • BehavioralHypocaloric Diet

    Hypocaloric diet

07

What researchers measure

Primary outcomes

  1. Total body weight loss

    In kg

    Time frame: 12 weeks

08

Study locations

1 site
  • St. Vincent's University Hospital
    Dublin, D04 T6F4, Ireland
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Mar 2021, 5 months.

Of 164 industry-sponsored interventional studies with no phase under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 5 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2019
First posted
Oct 1, 2019
StartActual
Oct 9, 2020
Primary completionActual
Mar 23, 2021
CompletionActual
Mar 23, 2021
Last update
Apr 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04110717
Lead sponsor
Neurovalens Ltd.
Collaborators
University College Dublin, Exploristics Ltd, Compliance Solutions Ltd.
Responsible party
Sponsor
First posted
Oct 1, 2019
Start date
Oct 9, 2020
Primary completion
Mar 23, 2021
Completion
Mar 23, 2021
Last update
Apr 3, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion